Aducanumab's EMERGE and ENGAGE phase 3 trials produced discordant efficacy results, making aducanumab a contested anti-amyloid translation precedent.

Evidence span

Aducanumab's EMERGE and ENGAGE phase 3 trials produced discordant efficacy results, making aducanumab a contested anti-amyloid translation precedent.

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Early Alzheimer's disease anti-amyloid antibody trials; two nominally parallel phase 3 studies.

Replicated

not yet

Confidence basis

Reduced from 0.460 to 0.460 (manual correction)